- Home
- GMAB vs APG Comparison
GMAB vs APG Comparison
Compare GMAB & APG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- APG
- Stock Information
- Founded
- GMAB 1999
- APG 1926
- Country
- GMAB Denmark
- APG United States
- Employees
- GMAB N/A
- APG N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- APG Engineering & Construction
- Sector
- GMAB Health Care
- APG Consumer Discretionary
- Exchange
- GMAB Nasdaq
- APG Nasdaq
- Market Cap
- GMAB 12.1B
- APG 10.1B
- IPO Year
- GMAB N/A
- APG N/A
- Fundamental
- Price
- GMAB $22.34
- APG $39.65
- Analyst Decision
- GMAB Buy
- APG Strong Buy
- Analyst Count
- GMAB 9
- APG 10
- Target Price
- GMAB $40.71
- APG $43.44
- AVG Volume (30 Days)
- GMAB 1.9M
- APG 1.3M
- Earning Date
- GMAB 02-12-2025
- APG 02-26-2025
- Dividend Yield
- GMAB N/A
- APG N/A
- EPS Growth
- GMAB 83.82
- APG N/A
- EPS
- GMAB 16.85
- APG N/A
- Revenue
- GMAB $2,988,286,182.00
- APG $6,916,000,000.00
- Revenue This Year
- GMAB $18.78
- APG $1.98
- Revenue Next Year
- GMAB $14.98
- APG $6.30
- P/E Ratio
- GMAB $13.00
- APG N/A
- Revenue Growth
- GMAB 30.67
- APG 0.64
- 52 Week Low
- GMAB $18.64
- APG $31.44
- 52 Week High
- GMAB $31.88
- APG $41.31
- Technical
- Relative Strength Index (RSI)
- GMAB 65.39
- APG 70.02
- Support Level
- GMAB $18.74
- APG $37.14
- Resistance Level
- GMAB $22.55
- APG $39.10
- Average True Range (ATR)
- GMAB 0.46
- APG 0.93
- MACD
- GMAB 0.39
- APG 0.27
- Stochastic Oscillator
- GMAB 94.64
- APG 88.16
About GMAB Genmab A/S ADS
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About APG APi Group Corporation
APi Group Corp operates in two segments: Safety Services segment includes providing safety services in North America, Asia Pacific, and Europe, focusing on end-to-end integrated occupancy systems (fire protection solutions, Heating, Ventilation, and Air Conditioning and entry systems), including design, installation, inspection, and service of these integrated systems. These services are provided in commercial, education, healthcare, high tech, industrial, and special-hazard settings. Specialty Services segment includes providing a variety of infrastructure services and specialized industrial plant services, which include maintenance and repair of critical infrastructure such as underground electric, gas, water, sewer, and telecommunications infrastructure.